RSS   Newsletter   Contact   Advertise with us

GW Pharmaceuticals appoints VP, clinical science

Staff writer | London, United Kingdom | May 7, 2014
GW PharmaceuticalsMay 7, 2014, London, United Kingdom - GW Pharmaceuticals plc, a biopharmaceutical company, announced the appointment of Kenneth Sommerville to the newly created position of VP, clinical science, based in the United States.
Mr. Sommerville is a board-certified neurologist and joins GW with significant experience, including 23 years of experience in the pharmaceutical industry.

He has had senior roles at UCB/Schwarz Pharma where he led clinical and regulatory programs in epilepsy and other neurological product development initiatives including NDA submissions to FDA and EMEA for multiple compounds.

Most recently, Mr. Sommerville served as Vice President of Clinical Sciences at Pfizer, Inc. where he was Global Clinical Lead for opioids and led a team of physicians and scientists in the development of abuse-deterrent opioids.

Mr. Sommerville also has led teams in multiple medical and scientific areas including, but not limited to, indications of complex partial seizures, basic and rapid infusion of an intravenous anti-convulsant, painful diabetic neuropathy, migraine prophylaxis, Parkinson's disease, bipolar disorder, personality disorders, and schizophrenia.

Mr. Sommerville has made major contributions to more than 20 NDA submissions for both the FDA and EMEA and is recognized as an authority in drug development, especially anti-epileptic drugs, pain, and abuse-deterrent opioids.

Mr. Sommerville earned a M.D. degree from Jefferson Medical College in Philadelphia, Pennsylvania and is an Adjunct Assistant Professor of Medicine at the Duke University Medical Center in Durham, North Carolina.

He was in the private practice of neurology for 11 years prior to entering the pharmaceutical industry.

 LATEST MOVES FROM United Kingdom